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A unifying feature of solid tumors is a markedly altered pH profile compared to
normal tissues. This reflects that solid tumors, despite completely different origins,
often share several phenotypic properties with implications for intra- and extracellular
pH. These include: a metabolic shift in most cancer cells toward more acid-producing
pathways, reflecting both oncogenic signaling and the development of hypoxia in poorly
perfused regions of the tumors; the poorly perfused and often highly dense tumor
microenvironment, reducing the diffusive flux of acid equivalents compared to that in
normal tissues; and the markedly altered regulation of the expression and activity of
pH-regulatory transport proteins in cancer cells. While some of these properties of tumors
have been well described in recent years, the great majority of the research in this clinically
important area has focused on proton transport, in particular via the Na+/H+ exchanger 1
(SLC9A1, NHE1) and various H+ ATPases. We have, however, recently demonstrated that
at least under some conditions, including in vitro models of HER2 positive breast cancer,
and measurements obtained directly in freshly dissected human mammary carcinomas,
bicarbonate transporters such as the electroneutral Na+, HCO−3 cotransporter (SLC4A7,
NBCn1), are upregulated and play central roles in pH regulation. In this review, we
summarize and discuss the current knowledge regarding the regulation and roles of
bicarbonate transporters in cancer. Furthermore, we present new analyses of publicly
available expression data demonstrating widely altered expression levels of SLC4- and
SLC26 family transporters in breast-, lung-, and colon cancer patients, and we hypothesize
that bicarbonate transporter dysregulation may have both diagnostic and therapeutic
potential in cancer treatment.
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INTRODUCTION AND OVERVIEW
Intracellular pH (pHi) homeostasis is a prerequisite for normal
cell function and requires, under most conditions, net extrusion
of acid equivalents to compensate for the metabolic acid produc-
tion and the H+ influx caused by the inwardly directed driving
force for this ion. Within the last decade, numerous studies have
demonstrated that pHi homeostasis is often dramatically altered
in cancer (for reviews see Gatenby and Gillies, 2008; Webb et al.,
2011; Boedtkjer et al., 2012; Parks et al., 2013; Pedersen and
Stock, 2013). This has sparked substantial interest in pH regu-
lation as a potential therapeutic target relevant to many forms
of cancer. It has been demonstrated that the high metabolic
demand of rapidly proliferating cancer cells, in conjunction with a
shift toward glycolytic metabolism reflecting both tumor hypoxia
and oncogene-induced changes in gene expression, leads to an
often greatly increased production of acid equivalents in can-
cer cells (see Kroemer and Pouyssegur, 2008; Cairns et al., 2011;
Cantor and Sabatini, 2012; Andersen et al., 2014). This notwith-
standing, cancer cells maintain a pHi that is equal to or even
sometimes more alkaline than their normal counterparts, imply-
ing that they upregulate net acid extrusion (see Webb et al., 2011;
Boedtkjer et al., 2012; Parks et al., 2013; Pedersen and Stock,
2013). This could, in principle, happen by upregulation of the
expression and/or activity of acid extruders or, conversely, by
downregulation of the expression and/or activity of acid load-
ing transporters—or by some combination thereof, and as will
be described below, there is indeed evidence for both in the
literature.
Plasma membrane transporters are highly interesting as
biomarkers and treatment targets in cancer, given their localiza-
tion at the cell surface, which renders them easily accessible for
e.g., immune-based therapies. Furthermore, acid-base membrane
transporters may represent an Achilles’ heel for many types of
cancers, which due to their high metabolic rates are predicted to
be more vulnerable to inhibition of acid extrusion than normal
cells. To date, however, only a few acid-base transporters have
received attention as potential culprits in the altered acid extru-
sion pattern in cancer cells. These are the Na+/H+ exchanger
isoform 1, SLC9A1 (NHE1) (e.g., Reshkin et al., 2000; Lauritzen
et al., 2010; Boedtkjer et al., 2013), the V-type H+ ATPases
(Sennoune et al., 2004; You et al., 2009; DeMilito et al., 2010), the
monocarboxylate transporter family lactate-proton transporters
(MCTs, Sonveaux et al., 2008; Halestrap, 2013), and, in a very few
cases, HCO−3 -coupled transporters (Ahmed et al., 2009; Lauritzen
et al., 2010; Chen et al., 2012; Boedtkjer et al., 2013); see (Parks
et al., 2013). With respect to the latter, the best studied in the
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context of cancer are the electroneutral Na+, HCO−3 cotrans-
porter, SLC4A7 (NBCn1) and the Cl−/HCO−3 exchanger Down-
regulated in Adenoma (SLC26A3, DRA): NBCn1 is upregulated
in breast cancer and single-nucleotide polymorphisms (SNPs) in
SLC4A7 have been linked to increased breast cancer risk while
DRA, as the name implies, is essentially lost early upon transfor-
mation in many colorectal cancers, and is thought to function as
a tumor suppressor.
The aim of this review is to summarize current knowledge on
HCO−3 transport in cancer, and to present and critically discuss
evidence regarding the involvement of altered HCO−3 transporter
expression and/or regulation in various cancers. We will first pro-
vide an overview of the existing evidence regarding the involve-
ment of the SLC4 (The SLC4 family in cancer—published studies)
and SLC26 (The SLC26 family and cancer—published studies)
families of HCO−3 transporters in various cancers. Because of the
wealth of information available on these two transporters com-
pared to the rest of the family members, SLC4A7 and SLC26A3
will be discussed separately in the sections SLC4A7 (NBCn1)
and Down-Regulated in Adenoma (SLC26A3, DRA), respectively.
Finally, in the section Novel Candidates: Other HCO−3 Transport
Proteins with Altered Expression in Cancer, we will explore the
expression profiles of the HCO−3 transporting SLC4 and SLC26
family members in various cancers, using publically available
databases, to set the scene for future studies on the regulation
and roles of HCO−3 transport in cancer. Based on the published
studies and our new datamining analyses presented here, we
hypothesize that HCO−3 transporter dysregulation may have both
diagnostic and therapeutic potential in cancer treatment.
THE SLC4 FAMILY IN CANCER—PUBLISHED STUDIES
The SLC4 family comprises 10 genes, of which at least 8 mediate
transport of HCO−3 (or related molecules, such as CO
2−
3 ) across
the plasma membrane (Figure 1). SLC4 family transporters play
central roles in pH homeostasis in a wide array of cell types
(see Parker and Boron, 2013; Romero et al., 2013). Detailed
accounts of the SLC4 family substrates, localization, physio-
logical functions and other pertinent properties can be found
elsewhere (see Parker and Boron, 2013; Romero et al., 2013)
and will not be provided here. Importantly, however, SLC4A1-3
(frequently denoted anion exchanger (AE) 1–3) are Cl−/HCO−3
exchangers, and at the intra- and extracellular ion concentra-
tions and membrane potential prevalent in most cell types under
normal conditions, these proteins will function as cellular acid
loaders. Conversely, SLC4A4 (NBCe1), −4A5 (NBCe2), −4A7
(NBCn1), −4A8 (NDCBE), and −4A10 (NCBE/NBCn2) are
Na+-coupled HCO−3 transporters, which are predicted to func-
tion as cellular acid extruders under the conditions prevalent in
most normal cell types. Exceptions are SLC4A4 in the kidney
and SLC4A5 in the choroid plexus, which are predicted to have
a 1Na+:3HCO−3 stoichiometry and serve as acid loaders (Millar
and Brown, 2008; Romero et al., 2013). It may be noted that
the sometimes very acidic extracellular pH (pHe) and consequent
low extracellular HCO−3 concentrations in tumors will diminish
the driving force for HCO−3 import, and could in extreme cases
render some of the “acid extruders” net acid importers in the
tumor setting. Assuming 150mM Na+o , 15mM Na+i , and 12mM
HCO−3 i (pHi ∼7.1), the 1Na+:1HCO−3 cotransporters will have
an inwardly directed driving force until pHe values as low as 6.1,
whereas 1Na+:2HCO−3 cotransporters will reverse at much more
modest extracellular acidifications.
As noted above, the great majority of studies of pHi dysreg-
ulation in cancer have focused on the Na+/H+ exchanger NHE1,
MCT family transporters, and V-type ATPases. Interestingly how-
ever, in recent years, several SLC4 family members have been
reported to be associated with cancer (Table 1). As mentioned,
the most widely studied of these is SLC4A7 (NBCn1), which has
been shown to be upregulated in human breast cancer (Boedtkjer
et al., 2013) as well as in cell culture by the ErbB2/HER2 onco-
gene (Lauritzen et al., 2010, 2012; Gorbatenko et al., 2014), which
is upregulated in up to a third of human mammary carcino-
mas and correlates with poor prognosis, and a SNP in which has
been linked to increased risk of breast cancer [see section SLC4A7
(NBCn1), Ahmed et al., 2009; Long et al., 2010; Han et al., 2011;
Sueta et al., 2012].
Dysregulation of several other members of the SLC4 family
has been linked to cancer development (Table 1). An interesting
series of studies relate the Cl−/HCO−3 exchangers SLC4A1
(AE1) and SLC4A2 (AE2) to gastrointestinal cancers. SLC4A1,
which is normally only expressed at detectable protein levels in
erythrocytes, was found to be markedly upregulated in gastric
cancer cells and colorectal cancer (CRC) cells (Shen et al., 2007),
and its expression to correlate with cancer progression (Xu
et al., 2009). Interestingly, SLC4A1 was not found in the plasma
membrane, but exclusively in the cytoplasm of these cells (Shen
et al., 2007). The tumorigenic effect of SLC4A1 was proposed
to involve a direct interaction of its C-terminal with the tumor
suppressor p16 (INK4a), sequestering the latter from the nucleus,
where it normally functions to inhibit cell cycle progression
(Shen et al., 2007). Thus, SLC4A1 was proposed to increase
gastric carcinogenesis by favoring cell proliferation, in a manner
apparently independent of effects on pHi regulation (Shen et al.,
2007). Knockdown of SLC4A1 reduced tumor progression in
two different mouse models of gastric cancer, a xenograft model
and chemical induction in conjunction with H. pylori (Suo et al.,
2012). Interestingly, the upregulation of SLC4A1 in gastric cancer
was recently found to be dependent on aberrant regulation by
miR-24, which normally silences SLC4A1 protein expression by
interaction with the 3′ untranslated region (UTR) of the gene
(Wu et al., 2010).
SLC4A2 (AE2) was found to be upregulated in CRC (Song
et al., 2012) and hepatocellular carcinoma (HCC) (Wu et al.,
2006; Hwang et al., 2009) and similar to SLC4A1 appears to
interact with p16 in the cytosol (Song et al., 2012). In CRC,
AE2 expression correlated with Ki67 proliferation marker stain-
ing and with poor prognosis (Song et al., 2012). In gastric cancer,
both upregulation (Wang et al., 2013) and downregulation (Yang
et al., 2008) of SLC4A2 has been reported, and this was pro-
posed to reflect that its expression is regulated by gastrin, the
expression of which varies between different gastric cancers and
cancer stages (Wang et al., 2013). Gastrin treatment decreased pHi
of human gastric cancer cells in a manner correlating with the
increased expression of SLC4A2 (Wang et al., 2013). On the other
hand, in CRC, gastrin treatment appeared to decrease SLC4A2
expression, by interfering with binding of EGR1 to the AE2a1
promoter (Song et al., 2012; Wang et al., 2013). Furthermore,
Frontiers in Physiology | Membrane Physiology and Membrane Biophysics April 2014 | Volume 5 | Article 130 | 2
Gorbatenko et al. Bicarbonate transporters in cancer
FIGURE 1 | Schematic model of HCO−3 transporters from the SLC4 and
SLC26 family. (A) SLC4 family transporters. (B) SLC26 family transporters. In
each panel, the left side shows the acid loaders and the right side shows the
acid extruders. It should be noted SLC4A4 in the kidney and SLC4A5 in the
choroid plexus are predicted to have a 1Na+:3HCO−3 stoichiometry and thus
would there serve as acid loaders (Millar and Brown, 2008; Romero et al.,
2013). Furthermore, SLC4A10 may additionally export Cl−; for the differing
viewpoints on this, compare (Parker et al., 2008) and (Damkier et al., 2010).
Other references: (Yoshitomi et al., 1985; Boron and Boulpaep, 1989; Virkki
et al., 2002; Alper and Sharma, 2013; Romero et al., 2013).
gastrin was found to reduce SLC4A1 expression in gastric can-
cer cells by eliciting its protein degradation (Tian et al., 2010).
Thus, the precise regulation of SLC4A1 and -A2 in gastrointesti-
nal cancers requires further elucidation and may be cell type
specific. Moreover, whereas in contrast to SLC4A1, SLC4A2 does
to some extent localize to the plasma membrane in the can-
cer cells (Song et al., 2012; Wang et al., 2013), it is not clear
from the published studies whether the role of the exchanger
in cancer progression involves both pHi regulation and p16
sequestration.
A SNP, rs13240966, located to an intronic region of the
SLC4A2 gene, was found to be associated with reduced risk
of bladder cancer, with an odds ratio for homozygotes of 0.6
(Andrew et al., 2009). On the other hand, this same SNP
significantly associated with susceptibility to myelodysplastic
syndromes—hematopoetic diseases that frequently become acute
leukemias—in a cohort of Czech patients (Belickova et al., 2013).
Impressively, homozygosity for this SNP was associated with an
odds ratio of 4.86 for myelodysplastic syndromes (Belickova et al.,
2013). It is to our knowledge unknown whether this intronic SNP
alters the protein expression pattern of SLC4A2, and the causal
link, if any, between SLC4A2 and myelodysplastic syndromes
still needs to be established. It is, however, well known that
transcriptional regulatory elements may be located in introns,
and regulation of ion transporter expression by an intronic SNP
has previously been reported (Tokuhiro et al., 2003).
Two studies of papillary thyroid cancers (PTC) in patients of
Polish (Galeza-Kulik et al., 2006) and Korean (Kim et al., 2010)
descent showed that mRNA expression of SLC4A4 (NBCe1) was
decreased by 7- and 3-fold, respectively, in PTC compared to
normal tissue. In contrast, a more recent study found SLC4A4
mRNA levels to be significantly (2.5 fold) upregulated in chronic
myeloid leukemia (CML) stem cells compared to normal stem
and progenitor cells, and was proposed as a possible target for
immune-based therapy due to its cell surface localization (Gerber
et al., 2013). Neither the mechanism(s) of SLC4A4 dysregulation
nor the possible causal role in CML were, however, addressed
in these studies. Interestingly, in a study in HT29 human CRC
cells, expression of SLC4A4 was shown to be negatively regulated
by miR-224 (Mencia et al., 2011). In HT29 cells with acquired
resistance to methotrexate (a folate- and metabolism-targeting
agent) chemotherapy, miR-224 was downregulated, resulting in
upregulation of SLC4A4. Notably, siRNA-mediated knockdown
of SLC4A4 resulted in increased sensitivity to methotrexate
treatment, and this was reversed upon anti-miR-224 transfection
(Mencia et al., 2011).
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Table 1 | Summary of the reported data on HCO−3 transporting SLC4 and SLC26 family transporters in cancer.
Transporter Alternative name Cancer Perturbation Functional link to cancer? References
SLC4A1 EPB3, AE1 Gastric, CRC Expression ↑↓ Correlates with cancer
progression
Shen et al., 2007; Xu et al.,
2009; Wu et al., 2010; Suo
et al., 2012
SLC4A2 EPB3L1, AE2 Gastric, CRC,
HCC, bladder
Expression ↓↑
SNP rs13240966
Poor prognosis, SNP—reduced
risk of bladder cancer
Wu et al., 2006; Yang et al.,
2008; Andrew et al., 2009;
Hwang et al., 2009; Tian
et al., 2010; Song et al., 2012;
Belickova et al., 2013; Wang
et al., 2013
SLC4A4 NBCe1 PTC, CML, CRC Expression ↓↑ Resistance to methotrexate Galeza-Kulik et al., 2006; Kim
et al., 2010; Mencia et al.,
2011; Gerber et al., 2013
SLC4A7 NBCn1 Breast cancer Expression (↓)↑
SNP rs4973768
Unknown, SNP—associated with
breast cancer risk
Chen et al., 2007; Ahmed
et al., 2009; Lauritzen et al.,
2010, 2012; Long et al., 2010;
Han et al., 2011; Mulligan
et al., 2011; Boedtkjer et al.,
2012, 2013; Fasching et al.,
2012; Sueta et al., 2012;
Fernandez-Navarro et al.,
2013; Gorbatenko et al., 2014;
SLC26A2 DTDST CRC Expression ↓ Reduced sulfation of sialyl Lewis
x ligand
Yusa et al., 2010
SLC26A3 DRA, CLD CRC, Instestina,
breast cancer
Expression ↓
Mutations
Reduces proliferation Schweinfest et al., 1993;
Hoglund et al., 1996; Antalis
et al., 1998; Hemminki et al.,
1998; Chapman et al., 2002;
Schweinfest et al., 2006;
Lauriola et al., 2010; Baker
et al., 2011; Dalerba et al.,
2011; Mosakhani et al., 2012;
de Ronde et al., 2013
SLC26A4 PDS, pendrin Thyroid cancer Expression ↓ Unknown Arturi et al., 2001; Porra et al.,
2002; Xing et al., 2003; Iwata
et al., 2011
Arrows (↑↓) indicate reported up- or down-regulation, respectively. See text for details. Abbreviations: EPB3, Erythrocyte Membrane Protein Band 3; AE1, Anion
Exchanger 1; EPB3L1, Erythrocyte Membrane Protein Band 3 Like 1; AE2, Anion Exchanger 2; NBCe1, Na+, HCO−3 electrogenic co-transporter 1; NBCn1, Na
+,
HCO−3 neutral co-transporter 1; DTDST, Diastrophic Dysplasia Sulfate Transporter; DRA, Down-Regulated in Adenoma; CLD, Congenital Chloride Diarrhoea; PDS,
Pendred Syndrome.
THE SLC26 FAMILY AND CANCER—PUBLISHED STUDIES
The second major group of mammalian plasma membrane
HCO−3 transporters is the SLC26 family. This family comprises
11 genes of which 8 have been shown to carry HCO−3 (see Alper
and Sharma, 2013). All of the SLC26 members function as anion
exchangers, and although the stoichiometry for these transporters
is not fully elucidated, they appear to most commonly serve as
cellular acid loaders (Figure 1). Three of them—SLC26A7, −9,
and −11 can additionally operate as anion channels (see Alper
and Sharma, 2013). Dysregulation of several members of this
family has been linked to cancer development (Table 1). As
noted above, one in particular has received widespread attention
for its dysregulation in CRC, namely SLC26A3, also known as
Downregulated in Adenoma (DRA), which was first described as
a gene downregulated in CRC in 1993 (Schweinfest et al., 1993).
The extensive body of evidence on the regulation and roles of
SLC26A3 in cancer is discussed in the section Down-Regulated
in Adenoma (SLC26A3, DRA).
A few other SLC26 family members have been linked to cancer.
Expression of SLC26A2 (DTDST), an exchanger carrying Cl−,
oxalate and SO2−4 , but not thought to transport HCO
−
3 (see Alper
and Sharma, 2013), was found to be strongly reduced in CRC,
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likely due to epigenetic silencing (aberrant histone methylation
and acetylation) (Yusa et al., 2010). This was assigned a role in
reducing sulfation of sialyl Lewisx and increasing proliferation
in CRC (Yusa et al., 2010). SLC26A4 (Pendrin) exhibits reduced
expression levels in thyroid cancers (Arturi et al., 2001; Porra
et al., 2002). The possible causal role of this downregulation in
cancer development is to our knowledge unknown, but given the
role of SLC26A4 as an anion exchanger capable of transporting
Cl−, HCO−3 , and I−, it is tempting to speculate that its downreg-
ulation may contribute to maintaining an elevated pHi in these
cells. A role for I− transport is of course also conceivable, how-
ever, the SLC26A4 knockout mouse has no thyroid phenotype
even under dietary iodide deficiency (Iwata et al., 2011), suggest-
ing that this transporter is not the main I− uptake pathway in
the thyroid. Interestingly, the 5′ region of the SLC26A4 gene was
found to be hyper-methylated as an early event in the majority of
malignant human thyroid tumors, presumably accounting for at
least part of the decreased SLC26A4 expression in these tumors
(Xing et al., 2003).
FUNCTION AND EXPRESSION OF HCO−3 TRANSPORTERS IN
CANCER
ROLES OF THE CARBONIC BUFFER SYSTEM IN TUMOR pH REGULATION
Recent studies from several laboratories have documented
the specific importance of HCO−3 in tumor pH regulation.
Intriguingly, it was demonstrated that oral administration of
HCO−3 could inhibit tumor metastasis in prostate-, breast- and
colon cancer cell line derived tumors. This apparently occurred
by reducing the extracellular acidity of the highly acid-extruding
tumors, in absence of changes in the pH of blood or normal
tissues (Robey et al., 2009; Silva et al., 2009; Wojtkowiak et al.,
2011; Estrella et al., 2013). Furthermore, early administration of
HCO−3 prevented carcinogenesis in Transgenic Adenocarcinoma of
the Mouse Prostate (TRAMP) mice, a model of prostate cancer
(Ibrahim-Hashim et al., 2012). Although the mechanisms under-
lying these effects are not absolutely clear, the authors suggest
that increased tumor pHe inhibits the activity of extracellular pro-
teases, such as Cathepsin B, in turn reducing invasiveness (Robey
et al., 2009). This hypothesis was recently supported by the
finding that in vivomatrix metalloproteinase and cathepsin activ-
ities, estimated by fluorescent reporters, are reduced in xenograft
tumors following NaHCO3 ingestion (Robey and Nesbit, 2013).
A recent study, however, points to the drawbacks and the possible
side effects of chronic HCO−3 administration such as metabolic
alkalosis and additionally suggests combinational therapy target-
ing proton production with dichloroacetate (DCA) (Martin et al.,
2012).
The importance of the carbonic buffer system in cancer is
also underscored by the ability of the hypoxia inducible carbonic
anhydrase IX (CAIX), which is upregulated in a wide variety of
cancers (Bartosova et al., 2002; Chen et al., 2005; Supuran, 2008;
Perez-Sayans et al., 2012), to increase HCO−3 -dependent resting
pHi and decrease pHe in Chinese hamster lung CCL39 fibrob-
lasts. CAIX knockdown has also been shown to reduce growth of
xenografts of LS174Tr colon cancer cells in nude mice (Chiche
et al., 2009). While most of the work on carbonic anhydrases in
cancer has focused on CAIX as a biomarker, studies from several
groups have highlighted the importance of the carbonic buffer
system for pH regulation in various cancer cell lines under nor-
mal, acidic, and hypoxic growth conditions When cancer cell
lines from pancreas, breast, and colon were grown in 2D culture,
the mechanism of net acid extrusion after an imposed acid load
varied between cell lines, from mainly HCO−3 influx to mainly
H+ efflux (Hulikova et al., 2011). Notably, at a pHe of 7.4, the
HCO−3 flux was rather similar between cell lines, whereas the
H+ efflux varied substantially (Hulikova et al., 2011). The ability
to recover from an imposed acid load was reduced by decreas-
ing pHe. This decrease could be mostly ascribed to reduced H+
efflux, whereas the HCO−3 influx was less affected by acidic pHe
(Hulikova et al., 2011). A similar pattern was observed after
exposing cancer cell lines to hypoxia, which reduced SLC9A1-
mediated H+ flux, whereas HCO−3 flux was hypoxia-insensitive
(Hulikova et al., 2013). Collectively, these studies suggest that
HCO−3 transport may serve a rather stable “housekeeping” role
in these cell lines, whereas H+ transport is highly variable and
attenuated under conditions of extracellular acidification and
hypoxia. As these conditions are prevalent in solid tumors (Vaupel
et al., 1981; Vaupel, 2004), the authors next addressed the mech-
anisms of pHi regulation in multicellular spheroids mimicking
the tumor 3D structure. These studies demonstrated that inhi-
bition of HCO−3 transport by 4,4′-diisothiocyanatostilbene-2,2′-
disulfonic acid (DIDS) generally lead to a non-uniform decrease
in the rate of pHi recovery after acid loading, with the greatest
effect of DIDS observed in the core of spheroids. Importantly, the
authors provide evidence that the carbonic buffer system plays a
dual role, supplying HCO−3 as substrate for transport and pro-
viding a mobile buffer facilitating the transport of the otherwise
poorly mobile H+ ions away from the cells. Thus, in MDA-MB-
468 breast cancer spheroids, which rely mainly on H+ transport
for pHi recovery, substitution of HCO
−
3 with 25mM HEPES had
no effect on the ability to recover from an acid load. However,
decreasing the concentration of HEPES elicited a non-uniform
pattern of pHi recovery with the slowest recovery at the core of the
spheroid consistent with CO2/HCO
−
3 (and under experimental
conditions HEPES) serving as a mobile buffer important for pHi
recovery under 3D conditions (Hulikova et al., 2011). Moreover,
the findings predict that because of the inhibitory effects of extra-
cellular acidification and hypoxia on SLC9A1, HCO−3 transport
will be progressively more important with distance from func-
tional blood vessels in the tumor. Finally, inhibition of either
SLC9A1 or HCO−3 transport attenuated spheroid growth, sug-
gesting that both types of transporters are important for cancer
cell survival and/or proliferation under 3D conditions (Hulikova
et al., 2011).
As mentioned above, the strongest evidence for involvement
of HCO−3 transporters in human cancer has been provided for
NBCn1 (SLC4A7) and DRA (SLC26A3). The current evidence
linking these two transport proteins to cancer will be addressed
below.
SLC4A7 (NBCn1)
The first link between this protein and breast cancer was pro-
vided when SLC4A7 was reported to be a tyrosine kinase substrate
in MCF10AT breast cancer cells and to be expressed at reduced
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levels in human breast cancer samples compared to matched nor-
mal breast tissue in a population of Asian women (Chen et al.,
2007). However, in the MCF10AT progression model, SLC4A7
expression was approximately three times higher in low- and
intermediate-grade lesions than in normal cells (Chen et al.,
2007) suggesting that at least early in breast cancer develop-
ment, SLC4A7 expression may be upregulated. The potential
importance of these observations was supported when multiple
genome-wide association studies (GWAS) subsequently showed
that a SNP in the SLC4A7 gene was linked to breast cancer:
independent GWAS covering women of European (Ahmed et al.,
2009), Korean (Han et al., 2011), Chinese (Long et al., 2010), and
Japanese (Sueta et al., 2012) descent showed that the rs4973768
SNP corresponding to the 3′-UTR of SLC4A7 is associated with
breast cancer with odds ratios for homozygosity between 1.2 and
1.3. The rs4973768 SNP has an allele frequency between 15 and
50% across the range of investigated ethnicities (Ahmed et al.,
2009; Long et al., 2010; Han et al., 2011; Sueta et al., 2012) and
thus could play a substantial role for human breast cancer devel-
opment. In carriers of the cancer susceptibility gene BRCA2, the
SNP was significantly associated with estrogen receptor (ER)-
positive, but not with ER-negative disease (Mulligan et al., 2011).
This suggests a possible link to ER signaling, which may also
underlie the apparent dependence of the breast cancer associa-
tion of this SNP on pre- or post-menopausal status (Chen et al.,
2012; Fernandez-Navarro et al., 2013).
Although it has been noted that the rs4973768 SNP may alter
the binding affinity of a microRNA binding site (Boedtkjer et al.,
2012) and thus alter SLC4A7 mRNA stability and translation, the
consequences of the rs4973768 SNP for SLC4A7 expression and
function have not yet been experimentally determined. Of note,
the rs4973768 SNP did not link to breast cancer survival in a large
GWAS study of 25853 breast cancer patients with available follow-
up data (Fasching et al., 2012).Moreover, there was no association
between rs4973768 andmammographic density—a risk factor for
breast cancer—except in a subgroup of pre-menopausal women
(Fernandez-Navarro et al., 2013).
Human breast cancer is a fairly heterogeneous disease, which
differs among others in expression levels for hormone (e.g., estro-
gen and progesterone) and growth factor (e.g., ErbB2) receptors.
The receptor status of the breast carcinomas modifies prognosis.
In particular, expression of a constitutively active, NH2-truncated
ErbB2 (NErbB2) receptor has been widely shown to confer
poor prognosis and limit treatment options (Christianson et al.,
1998). In this light, it is interesting that heterologous expres-
sion of the NErbB2 receptor in human MCF-7 breast cancer
cells enhances expression of SLC4A7 and cellular acid extrusion
activity (Lauritzen et al., 2010).
Recent studies from our group demonstrated that NErbB2-
dependent SLC4A7 upregulation is controlled via Akt-, ERK-
and Src-dependent pathways (Gorbatenko et al., 2014; Figure 2).
Inhibition or siRNA-mediated knockdown of these kinases
decreased SLC4A7 mRNA and protein levels. Furthermore, the
SLC4A7 promoter was characterized in detail. Although SLC4A7
was suggested to have several alternative promoters, all epigenetic
marks, correlating with presence of actively transcribed chro-
matin, such as H3K27Ac and H3K27me3, were only detectible
near the first possible SLC4A7 exon. The SLC4A7 core promoter
is TATA-box-less, yet contains a large GC rich region. Despite the
fact that CpG island containing promoters usually exhibit broad
transcription initiation, Cap Analysis of Gene Expression (CAGE)
data from MCF-7 breast cancer cells suggested a single base-
focused transcription start site (TSS) and the sequence around it
perfectly resembled an initiator (Inr) element (Gorbatenko et al.,
2014). Luciferase reporter assays of the putative SLC4A7 pro-
moter region demonstrated that mutation of the Inr element led
to 50% loss of promoter activity (Figure 2). NErbB2 signaling
stimulated the promoter activity by ∼2.5 fold and further dele-
tions identified the minimal, NErbB2 sensitive region within
the promoter. Two related transcription factors with known
roles in cancer, Sp1 and KLF4, bind to the SLC4A7 promoter,
exerting opposite functions: Sp1 represses and KLF4 activates
SLC4A7 transcription (Gorbatenko et al., 2014). Notably, KLF4-
dependent transcription was stimulated by NErbB2 signaling
and this was at least partially controlled by Akt1 and ERK1 kinases
(Figure 2). Finally, stimulation of full-length ErbB2 receptors
in SKBr3 breast cancer cells increased both SLC4A7 expres-
sion and HCO−3 -dependent pHi recovery (Gorbatenko et al.,
2014).
Although the initial investigations in a population of Asian
women suggested that the expression levels for SLC4A7 are
reduced in breast cancer tissue compared to normal breast tis-
sue (Chen et al., 2007), this has not subsequently been con-
firmed. In contrast, based on tissue samples from women of
European descent, we recently showed that the plasma mem-
brane expression of SLC4A7 is upregulated in human primary
breast carcinomas and metastases compared to matched normal
breast tissue (Boedtkjer et al., 2013). We furthermore showed
that Na+, HCO−3 cotransport of low sensitivity to DIDS, a hall-
mark of epithelial SLC4A7-mediated HCO−3 transport, (Parker
and Boron, 2013) is the predominant mechanism of acid extru-
sion in freshly isolated slices of human primary breast carci-
nomas (Boedtkjer et al., 2013). Interestingly, only 10–20% of
the investigated human breast carcinomas in our study showed
upregulation or gene amplification of the ErbB2 receptor, sug-
gesting that upregulated SLC4A7 expression is of general impor-
tance in breast cancer and not restricted to cancers charac-
terized by increased ErbB2 signaling (Boedtkjer et al., 2013).
The enhanced expression of SLC4A7 and its putative role in
cellular acid extrusion would imply that SLC4A7 is involved
in establishing the characteristically high pHi and low pHe
observed in breast carcinomas. In congruence, steady-state pHi
in slices of human primary breast carcinomas decreased around
0.35 units upon omission of CO2/HCO
−
3 (Boedtkjer et al.,
2013).
RELATIVE ROLES OF SLC4A7 (NBCn1) AND SLC9A1 (NHE1) IN CANCER
In most cell systems, Na+, HCO−3 cotransport acts in paral-
lel with Na+/H+ exchange to extrude intracellular acid loads,
and a brief discussion of their relative roles in cancer is there-
fore warranted. Multiple studies have demonstrated that Na+/H+
exchange plays a significant role in cancer cells (Reshkin et al.,
2013) and xenograft studies have shown that Na+/H+ exchange
deficiency inhibits tumor growth of MGH-U1 bladder carcinoma
Frontiers in Physiology | Membrane Physiology and Membrane Biophysics April 2014 | Volume 5 | Article 130 | 6
Gorbatenko et al. Bicarbonate transporters in cancer
FIGURE 2 | SLC4A7 expression regulation by the truncated ErbB2
receptor. (A) SLC4A7 mRNA and protein levels. MCF-7 cells with a stably
cloned N-terminally truncated ErbB2 receptor under control of a
tetracycline-off promoter (MCF-tTA-NErbB2; here referred to as NErbB2
cells) and corresponding vector controls (MCF-tTA-pTRE; referred to as vector
cells) were used. At given time points, after tetracycline removal, cells were
lysed or paraformaldehyde fixed. Left: mRNA levels were assessed using
SYBRGreen qPCR. ∗∗∗P < 0.001 compared to vector cells at 24 h. ## Indicate
P < 0.05 and P < 0.01, respectively, compared to the corresponding time
point in vector cells. Right: protein levels, representative Western blot.
Below: Representative immunofluorescence image. (B) SLC4A7 promoter
(Continued)
www.frontiersin.org April 2014 | Volume 5 | Article 130 | 7
Gorbatenko et al. Bicarbonate transporters in cancer
FIGURE 2 | Continued
activity and regulation by ErbB2. Cells were co-transfected with the pGL3
basic vector, in which the relevant DNA constructs were cloned upstream of
the firefly luciferase gene. Promoter activity was assessed by dual luciferase
assays. At 24 h after tetracycline removal to induce NErbB2 expression, cells
were transfected with the indicated constructs and with the pHRG-B vector
carrying Renilla luciferase, and luciferase activity was measured another 24 h
later. Data are shown as firefly luciferase activity normalized to Renilla
luciferase activity, relative to that in vector cells. Numbers indicate sequence
length; − and + indicate sequence position up- or down-stream, respectively,
of the TSS obtained from CAGE data. Blue rhombuses and red circles indicate
binding sites for KLF4 and Sp1, respectively. Only binding sites with relative
profile score threshold >90% of Jaspar position weight matrices (PWMs) are
depicted. Data are from 3 to 6 independent experiments/conditions.
∗∗P < 0.01, ∗∗∗P < 0.001 vs. full-length sequence in same cell type unless
indicated with a line; ###P < 0.001 vs. other cell type in same conditions.
(C) Model of ErbB2 dependent SLC4A7 expression regulation. See text for
details. Data in (A) are from Lauritzen et al. (2010), except immunofluorescence
data, which are unpublished data by C.W. Olesen. Data in (B) and the model in
(C) are redrawn with permission, from Gorbatenko et al. (2014).
cells (Rotin et al., 1989). SLC9A1 has been shown to contribute
to pHi regulation in cultured MCF-7 cells (Lauritzen et al.,
2010) and human breast cancer slices (Boedtkjer et al., 2013).
In MCF-7 cells, no significant change in SLC9A1 expression was
observed in response to heterologous expression ofNErbB2, yet
the contribution of SLC9A1 to cellular acid extrusion was sub-
stantial (Lauritzen et al., 2010) and NErbB2 expression was
associated with increased phosphorylation of SLC9A1 at Ser703
(Lauritzen et al., 2012), which has previously been shown to
increase SLC9A1 activity (Takahashi et al., 1999). In the human
breast cancer slices, Na+/H+ exchange contributed to net acid
extrusion primarily at low pHi values (Boedtkjer et al., 2013).
Although the role of Na+/H+ exchange may be less obvious
than the role of Na+, HCO−3 cotransport for cellular net acid
extrusion and global steady-state pHi control in breast carci-
nomas (Boedtkjer et al., 2013), cell culture experiments have
clearly demonstrated that SLC9A1 plays a prominent and spe-
cific role for modulating cell migration, survival, growth and
proliferation (Stock and Schwab, 2006; Schwab et al., 2012).
These effects may in part be explained by changes in pH in local
restricted compartments (Ro and Carson, 2004) or may be due
to transport-independent interactions with intra- or extracel-
lular structural components or with cellular signaling cascades
(Stock and Schwab, 2006). Initial studies to explore whether
SLC4A7 plays a similar role for cell migration have been con-
ducted using pharmacological inhibitors of Na+/H+ exchange
(5-(N-ethyl-N-isopropyl) amiloride, EIPA) and Na+, HCO−3
cotransport (S0859) in NErbB2-expressing MCF-7 breast can-
cer cells: EIPA was surprisingly shown to enhance cell migration
while S0859 had no effect (Lauritzen et al., 2012). An earlier
study suggested that the electrogenic Na+, HCO−3 cotransporter
NBCe1 had a minor stimulatory role on migration in trans-
formed Na+/H+ exchange deficientMadin-Darby Canine Kidney
(MDCK) cells (Schwab et al., 2005), providing evidence that Na+,
HCO−3 cotransport canmodulate cell motility at least in some cell
systems.
Since SLC4A7 is also expressed in the smooth muscle and
endothelial cells of the vascular wall (Boedtkjer et al., 2008)
and is important for maintaining vasomotor responsiveness
(Boedtkjer et al., 2011) and possibly arterial structure (Boedtkjer
and Aalkjaer, 2013), it is conceivable that SLC4A7 may also in
part affect cancer development by modifying blood perfusion
of tumors. Efficient acid extrusion mechanisms in the vascular
smooth muscle cells and endothelial cells of tumor vessels would
be expected to be particularly important due to the high local acid
load.
DOWN-REGULATED IN ADENOMA (SLC26A3, DRA)
SLC26A3 was first described based on its reduced expression lev-
els in colorectal adenomas and adenocarcinomas compared to
normal colon epithelium (Schweinfest et al., 1993). Subsequently,
SLC26A3 was reported to function as a Cl−/anion exchanger in
the luminal membrane of the gastrointestinal tract and was pro-
posed to contribute to transepithelial HCO−3 secretion (Jacob
et al., 2002). The anions transported by SLC26A3 appear to
include Cl−, HCO−3 and SO
2−
4 while transport of oxalate is lim-
ited (Jacob et al., 2002). Since SLC26A3 can remove HCO−3 from
cells, it is possible that lower expression of SLC26A3 reduces the
net acid load on the cells and eases the elimination of acidic
waste products produced by cancer cell metabolism. The role of
SLC26A3 for pHi regulation in colon carcinomas, however, needs
further investigation.
Mutation of SLC26A3—in addition to causing congenital
chloride diarrhea (Hoglund et al., 1996)—increases the risk of
intestinal cancer (Hemminki et al., 1998). It is not clear at this
point, however, whether the correlation between SLC26A3 and
colon cancer is due to its role in HCO−3 transport (and hence to
regulation of pHi and local pHe), a role in cellular Cl− homeosta-
sis, or other less understood functions. Interestingly, mutations
in the Cl− channel Cystic Fibrosis Transmembrane conductance
Regulator (CFTR), which is expressed in the luminal membrane
of colonic crypt cells (Crawford et al., 1991), have also been sug-
gested to be inversely associated with colon cancer (Padua et al.,
1997), supporting the possibility for Cl−-dependent effects of
SLC26A3. SLC26A3 has, furthermore, been proposed to mod-
ify cellular growth: heterologous expression of SLC26A3 induces
growth suppression in various cancer cell lines (Chapman et al.,
2002) while SLC26A3 knockout mice display altered morphol-
ogy of the colonic mucosa with an expanded proliferative zone
(Schweinfest et al., 2006). In combination, these findings suggest
multiple possible roles of SLC26A3 in cancer development, and
additional experimental investigations are required to further our
mechanistic understanding. Notably, however, SLC26A3 expres-
sion, together with expression of three other genes, had predictive
value for survival in patients with CRC of the wild type KRAS
type (Baker et al., 2011).
SLC26A3 downregulation correlates with colon tumor pro-
gression (Antalis et al., 1998); and in congruence with this,
expression levels for SLC26A3 have been reported to be con-
trolled by miR-31, which is upregulated in tumors from patients
with progressive CRC compared to patients with disease con-
trol (Mosakhani et al., 2012). Although SLC26A3 has been
shown to be a prognostic marker in colon cancer (Dalerba
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et al., 2011), a potential causative role of SLC26A3 expression in
colon carcinogenesis is still controversial: some investigators have
shown that SLC26A3 expression correlates with cell differentia-
tion, i.e., expression of SLC26A3 occurs preferentially in highly
differentiated colonic epithelial cells but is low in dedifferentiated
cells (Hoglund et al., 1996). The association between SLC26A3
expression levels and cellular differentiation in the normal epithe-
lium, however, does not appear to be recapitulated in tumors
since SLC26A3 expression has been shown to be reduced in both
differentiated and dedifferentiated tumors (Antalis et al., 1998).
Since cancer cells are generally dedifferentiated compared to nor-
mal epithelial cells, however, it cannot currently be excluded
that reduced expression of SLC26A3 in colorectal adenocarcino-
mas is a consequence of the dedifferentiated state rather than a
mechanistic cause of malignant development.
Since SLC26A3 is expressed in colonic epithelium but not in
blood cells, detection of circulating tumor cells by identification
of SLC26A3mRNAwas suggested as a screeningmethod for CRC,
but the specificity has so far been too low for SLC26A3 to qualify
as a clinically useful marker (Lauriola et al., 2010).
It is currently unclear from the literature whether SLC26A3 is
also of relevance to other types of cancer (see, however, the section
Novel Candidates: Other HCO−3 Transport Proteins with Altered
Expression in Cancer); but consistent with more general implica-
tions, SLC26A3 was recently shown to be a marker of resistance
to neoadjuvant chemotherapy in ErbB2 receptor negative breast
cancer (de Ronde et al., 2013).
NOVEL CANDIDATES: OTHER HCO−3 TRANSPORT PROTEINS
WITH ALTERED EXPRESSION IN CANCER
In the previous sections, we have discussed the published lit-
erature on HCO−3 transporters in relation to cancer. As evi-
dent from this, only a few studies directly addressing this issue
are yet available, and for most HCO−3 transporters, their pos-
sible relation to cancer development is completely uninvesti-
gated. In order to identify novel potential candidates for dys-
regulation of HCO−3 transport in cancer, we have mined two
authoritative bioinformatics sources: The Catalog of Somatic
Mutations in Cancer (COSMIC) database of cancer-associated
mutations (http://cancer.sanger.ac.uk, Forbes et al., 2011) and
The Cancer Genome Atlas (TCGA, http://cancergenome.nih.
gov/), the latter using the Cancer Genomics Browser (https://
genome-cancer.ucsc.edu/,
2013).
Table 2 summarizes mutation rates for SLC4 and SLC26 mem-
bers extracted from COSMIC. As seen, the mutation rates for
the SLC4 and SLC26 families vary markedly between the five
different cancer types shown. Less than 1% of the genes from
these two families exhibit somatic mutations in breast and pan-
creatic cancer. In contrast, in endometrial cancers, the mutation
rate is 5% or higher for almost all of the SLC4 and SLC26
genes. This should be seen in the light of the generally high
frequency of genomic instability in endometrial cancers (Matias-
Guiu and Prat, 2013), however, it would be highly interesting to
assess whether any of these mutations alter transporter function.
In colon and lung cancer, the mutation rates are very differ-
ent between the different genes, but it is interesting to note
Table 2 | Somatic mutation rates for SLC4 and SLC26 family
transporters in different cancer types.
Data are obtained from the COSMIC cancer mutation database. See text for
details.
that overall, the SLC4 family has a higher mutation rate com-
pared to the SLC26 family in these two cancer types. These data,
while preliminary, suggest that mutations in HCO−3 transporters
could be present in multiple cancers and it would be interest-
ing to address in future studies whether specific mutations with
effects on transporter function might contribute to the cancer
phenotype.
Figures 3–5 illustrate results from TGCA datasets on the
mRNA expression profiles of SLC4 and SLC26 members (exclud-
ing those known not to carry HCO−3 ) and selected carbonic
anhydrases (CAII, CAIX, and CAXII) in breast- (Figure 3), colon-
(Figure 4), and lung cancer (Figure 5), respectively.
As seen in Figure 3, firstly, the mRNA expression levels of most
of the SLC4 and SLC26 family members differ widely between
normal and cancer tissue, with a clear trend toward upregu-
lation of SLC4A3, SLC4A7, and SLC26A6, and downregulation
of SLC4A1 in cancer compared to normal tissue. Second, the
two major subtypes of lung cancer (squamous cell carcinoma
and adenocarcinoma) differ markedly in expression of the two
families of transporters. For example, SLC4A4, SLC4A8, and
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FIGURE 3 | SLC4 and SLC26 family mRNA expression levels in lung
cancer. RNA sequencing data (ID: TCGA_LUNG_exp_HiSeqV2, N = 1081)
from The Genome Cancer Atlas database was processed and visualized with
UCSC Cancer Genomics Browser (https://genome-cancer.ucsc.edu). The
color scale represents changes of gene expression: up-regulation (red),
down-regulation (green) or no change (black). Data is expressed as log2
transformed RNA-seq RSEM counts normalized to log2 transformed mean of
the dataset.
SLC26A9 are down-regulated in squamous cell carcinoma, but
not in adenocarcinoma of the lung.
The different subtypes of breast cancer (Figure 4) show an
even more heterogeneous expression pattern of SLC4 and SLC26
family transporters. Especially basal breast cancers are distinct
from the other subtypes, with markedly different expression
patterns of many of these proteins compared to the other sub-
types, including an apparent strong and consistent upregula-
tion of SLC26A9. However, some general trends are observed
across all breast cancer subtypes: SLC4A1, SLC4A4, SLC26A3, and
SLC26A4 seem to be consistently down-regulated, while SLC4A5
is up-regulated, in all breast cancer subtypes compared to nor-
mal breast tissue. Of note, the TCGA data show no consistent
upregulation of SLC4A7 mRNA levels in cancer, which is at
variance with the pattern indicated from protein level data in
(Boedtkjer et al., 2013).
Finally, in colon adenocarcinomas (Figure 5), the TCGA
data indicate that mRNA levels of SLC4A1, SLC4A4, SLC4A10,
SLC26A3, SLC26A4, and SLC26A7 are down-regulated, while
SLC4A2 and SLC4A5 tend to be up-regulated, compared to
normal colon tissue. Thus, consistent with published findings
[see section Down-Regulated in Adenoma (SLC26A3, DRA)],
SLC26A3 is down-regulated in colon cancer, but furthermore,
our analyses reveal that this gene is also widely down-regulated
in breast cancer (Figure 4).
Interesting patterns are also seen when comparing the expres-
sion patterns of three carbonic anhydrases implicated in cancer
development: CAII, CAIX, and CAXII, to each other and to that
of the HCO−3 transporters. Firstly, while CAII mRNA levels are
generally down-regulated through lung and colon cancer datasets
(less so in breast cancer), CAIX andCAXII seem to be expressed in
a highly cancer subtype-specific manner. For instance, the CAIX
mRNA level is strongly increased in basal and triple-negative
breast cancers, while the CAXII mRNA level is generally increased
in all breast cancer subtypes except the triple-negative breast can-
cers. Also interestingly, the mRNA levels of both CAIX and CAXII
are increased in squamous cell carcinoma of the lung, yet not in
lung adenocarcinomas. Second, marked co-expression patterns
are notable between specific CAs and specificHCO−3 transporters.
For instance, the high levels of CAIX and CAXII in squamous cell
carcinomas and low levels in adenocarcinoma is accompanied by
an almost opposite expression pattern of the HCO−3 transporters,
levels of which are generally high in adenocarcinoma and low
in squamous cell carcinoma, the only exception being SLC4A3.
Another example is the expression pattern of SLC26A9 and CAIX
in breast cancer, which is strikingly similar, with high levels in
basal and triple-negative breast cancers only. While this of course
needs further, unequivocal validation, we hypothesize that such
distinct patterns might be useful in the differentiation between
specific cancer subtypes, both in breast and lung cancer.
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FIGURE 4 | SLC4 and SLC26 family mRNA expression levels in breast
cancer. RNA sequencing data (ID: TCGA_BRCA_exp_HiSeqV2, N = 1106)
from The Genome Cancer Atlas database was processed and visualized with
UCSC Cancer Genomics Browser (https://genome-cancer.ucsc.edu). The
color scale represents changes of gene expression: up-regulation (red),
down-regulation (green) or no change (black). Data is expressed as log2
transformed RNA-seq RSEM counts normalized to log2 transformed mean of
the dataset.
The juxtaposition of all the HCO−3 transporter expression data
in Figures 3–5 begs the question of whether there are patterns
reflecting the functional categories of transporters, i.e., anion
exchangers vs. Na+-coupled 1:1 or 1:2 HCO−3 transporters. In
general, however, apart from co-expression patterns like those
described above, no strong such pattern emerges. Collectively,
our analyses of publicly available gene expression data con-
firm the notion that many HCO−3 transporters exhibit markedly
altered expression patterns in cancer compared to normal tissue.
However, the data does not reveal an explicit trend consistent
with the notion that HCO−3 extruders would be down-regulated
and HCO−3 loaders up-regulated in solid tumors. Moreover, dif-
ferent subtypes of the cancers studied exhibit different HCO−3
transporter expression profiles, in congruence with the known
heterogeneity of genetic and epigenetic changes in cancer. Finally
and importantly, these data reveal nothing about the possible
posttranslational regulation of these transporters, which could
result in an activity profile completely different from the expres-
sion profile. It seems likely that the specific HCO−3 transporter(s)
expressed might be subject to great variance between cancer types
and subtypes, whereas the functional correlate—increased net
acid extrusion capacity—would be more similar. However, also at
the functional level, substantial differences are expected, depend-
ing, e.g., on metabolic differences between cancer types. Future
studies should focus on revealing the mechanisms of regulation
of HCO−3 transporter expression and activity and the possible
functional relevance of the changes observed here, for cancer
development. Given the increasing evidence pointing toward a
major importance of pH-regulatory ion transport dysregulation
in cancer development, we hypothesize that altered HCO−3 trans-
porter expression, if paralleled by increased activity, is likely to
play a causal role in at least some cancers, and hence, that these
transporters are potentially relevant as therapeutic targets.
CONCLUSIONS AND OUTLOOK
While the great majority of the research on the roles of pHi dys-
regulation in cancer development has focused on H+ transport,
recent evidence indicates that also HCO−3 transport is dysregu-
lated inmany cancers. The few studies available to date addressing
the importance of HCO−3 transport for pHi regulation and cancer
cell growth show that particularly under 3D conditions, HCO−3
transport appears to play a central role. The new datamining anal-
yses presented here suggests that many more HCO−3 transporters
than those studied to date may be dysregulated in various cancers,
and we hypothesize that this may have both diagnostic and ther-
apeutic potential. However, most of the central questions remain
open, including the mechanisms of transporter dysregulation, the
possible causal role of the dysregulation for cancer development,
and the extent to which such a role reflects the involvement of the
transporters in pHi regulation. Furthermore, it will be essential to
validate the putative roles of HCO−3 transporters in in vivomodels
of cancer.
www.frontiersin.org April 2014 | Volume 5 | Article 130 | 11
Gorbatenko et al. Bicarbonate transporters in cancer
FIGURE 5 | SLC4 and SLC26 family mRNA expression levels in colorectal
cancer. RNA sequencing data (ID: TCGA_COAD_exp_HiSeqV2, N = 272)
from The Genome Cancer Atlas database was processed and visualized with
UCSC Cancer Genomics Browser (https://genome-cancer.ucsc.edu). The
color scale represents changes of gene expression: up-regulation (red color),
down-regulation (green) or no change (black). Data is expressed as log2
transformed RNA-seq RSEM counts normalized to log2 transformed mean of
the dataset.
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